IL17A and ankylosing spondylitis: The aim of the study is to compare the clinical and cost-effectiveness of IL-17 inhibitors (secukinumab, ixekizumab, and netakimab) in the treatment of adult patients with ankylosing spondylitis within the healthcare system of the Russian Federation.